Top

Published in:

01-01-2014 | Hepatobiliary Tumors

Systemic Therapy for Patients with Resectable Hepatic Colorectal Metastases: Improving Patient Selection

Authors: William R. Jarnagin, MD, Michael D’Angelica, MD

Published in: Annals of Surgical Oncology | Issue 1/2014

Excerpt

The past three decades have seen great changes in the management of hepatic colorectal cancer metastases. While resection remains firmly established as the most effective therapy for selected patients, the emergence of more effective chemotherapeutic agents has been a practice changing development and has considerably altered the therapeutic approach to patients with this disease. …

Power DG, Kemeny NE. Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection. Crit Rev Oncol Hematol. 2011;79(3):251–64.PubMedCrossRef

Chan KM, Chiang JM, Lee CF, et al. Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment. World J Surg Oncol. 2011;9:174.PubMedCentralPubMedCrossRef

House MG, Ito H, Gönen M, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210:744–52, 752–5.

Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66.PubMedCrossRef

Andres A, Majno PE, Morel P, et al. Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score. Ann Surg Oncol. 2008;15:134–143.PubMedCrossRef

Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008;26:4906–11.PubMedCrossRef

Ychou M, Hohenberger W, Thezenas S, et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol. 2009;20:1964–70.PubMedCrossRef

Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007–16.PubMedCentralPubMedCrossRef

Nordlinger B, Sorbye H, Glimelius B, et al. EORTC liver metastases intergroup randomized phase III study 40983: long-term survival results. J Clin Oncol. (Meeting Abstracts) 2012;30(15_Suppl):3508.

10.

Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer. 1996;77:1254–62.PubMedCrossRef

11.

Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18.PubMedCrossRef

12.

Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 1999;189:291–9.PubMedCentralPubMedCrossRef

13.

Nagashima I, Takada T, Matsuda K, et al. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. J Hepatobiliary Pancreat Surg. 2004;11:79–83.PubMedCrossRef

14.

Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125–35.PubMedCrossRef

15.

Konopke R, Kersting S, Distler M, et al. Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int. 2009;29:89–102.PubMedCrossRef

16.

Hirokawa F, Hayashi M, Miyamoto Y, et al. Reconsideration of the indications for adjuvant chemotherapy for liver metastases from colorectal cancer after initial hepatectomy. Ann Surg Oncol. 2013 (in press).

Title: Systemic Therapy for Patients with Resectable Hepatic Colorectal Metastases: Improving Patient Selection
Authors: William R. Jarnagin, MD
Michael D’Angelica, MD
Publication date: 01-01-2014
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 1/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-013-3312-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Systemic Therapy for Patients with Resectable Hepatic Colorectal Metastases: Improving Patient Selection

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2014

Mucinous Tumor of the Appendix with Limited Peritoneal Spread: Is There a Role for Expectant Observation?

Significance of mTOR Signaling and Its Inhibitor Against Cancer Stem-Like Cells in Colorectal Cancer

Laparoscopic Right Hepatectomy Extended to Middle Hepatic Vein After Right Portal Vein Embolization

Down-Regulation of Stromal Caveolin-1 Expression in Esophageal Squamous Cell Carcinoma: A Potent Predictor of Lymph Node Metastases, Early Tumor Recurrence, and Poor Prognosis

Impact of Margin Assessment Method on Positive Margin Rate and Total Volume Excised

MRI-Based Treatment of Rectal Cancer: Is Prognostication of the Recurrence Risk Solid Enough to Render Radiation Redundant?